Related Experiment Videos
[Drug-induced hepatitis caused by Fansidar]
1Innere Abteilung des Diakonissenkrankenhauses Mannheim.
Schweizerische Medizinische Wochenschrift
|October 3, 1987
Summary
Recurrent cholestatic hepatitis was diagnosed in a patient who traveled to tropical regions. Further investigation revealed Fansidar, an antimalarial drug, as the cause of liver damage.
Area of Science:
- Hepatology
- Tropical Medicine
- Clinical Toxicology
Background:
- Recurrent cholestatic hepatitis presents a diagnostic challenge, particularly in patients with travel history.
- Non-A-non-B hepatitis is a diagnosis of exclusion, requiring thorough investigation to rule out other causes.
Observation:
- A 27-year-old patient presented with recurrent episodes of cholestatic hepatitis.
- Symptoms consistently emerged following travel to tropical endemic areas.
Findings:
- Exclusion of common infectious hepatitis etiologies was performed.
- Careful clinical exploration identified Fansidar (a combination antimalarial drug) as the causative agent responsible for the liver damage.
Implications:
- This case highlights the importance of considering drug-induced liver injury (DILI) in patients with recurrent hepatitis, especially after travel.
- Clinicians should inquire about specific medication use, including antimalarials like Fansidar, in the differential diagnosis of unexplained hepatitis.
- Awareness of Fansidar's hepatotoxicity is crucial for preventing recurrent liver injury in susceptible individuals.